Galil Medical Announces Support of American Urological Association’s Tissue Ablative Course: Kidney and Prostate

Share Article

Cryotherapy is a minimally invasive treatment for both prostate and kidney cancer

Galil Medical, a global leader in minimally invasive cryotherapy cancer treatments, announced today that they are a key supporter of the upcoming AUA course on tissue ablation, to be held in Miami on November 12-13, 2010.

The CME accredited course will focus on ablative technologies, including cryotherapy, and its role in the treatment of both prostate and kidney cancers.

The audience for this course is practicing urologists or interventional radiologists who are interested in expanding the clinical application of ablation into their practice.

“Ablation is an increasingly important treatment option for both physicians and patients to consider. This course will provide physicians with the latest information on the different ablative technologies, as well as patient selection and clinical outcomes. Additionally, this course is specifically designed to help transfer important skills including laparoscopic kidney cryoablation, CT guided kidney cryoablation and prostate cryoablation,” said Jaime Landman, MD, Associate Professor, Department of Urologic Surgery, Columbia University Medical Center and Course Co-Director.

Minimally invasive ablative therapies are increasingly accepted treatment options due to favorable clinical outcomes, reduced procedural pain, fewer complications and faster patient recovery.

Martin J. Emerson, President and CEO of Galil Medical commented, “Our goal is to make cryotherapy a more widely accepted treatment option for the treatment of prostate and kidney cancer. We are proud to support the AUA in their endeavor to educate physicians on the different ablative technologies, including cryotherapy.”

About Galil Medical Galil Medical is a global leader in delivering innovative cryotherapy solutions. The company is addressing patient conditions across multiple physician specialties; treatment areas include conditions affecting bone, kidney, liver, lung and prostate, as well as targeted pain applications. Company offices are in Arden Hills, Minnesota; Yokneam, Israel; and London, United Kingdom. Shareholders include Thomas, McNerney & Partners, The Vertical Group, and Investor Growth Capital.

Contact information:

Martin J. Emerson
President and CEO, Galil Medical
Tel: +1 651 287 5050
Email: marty(dot)emerson(at)galilmedical(dot)com

Tres Glenn
Vice-President, Global Marketing, Galil Medical
Tel: +1 919 673 5863
Email: tres(dot)glenn(at)galilmedical(dot)com


Share article on social media or email:

View article via:

Pdf Print

Contact Author

Tres Glenn
Visit website